#BEGIN_DRUGCARD DB01361

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Cyclamycin
Evramicina
Matromicina
Tao
Treolmicina
Tribiocillina

# CAS_Registry_Number:
2751-09-9

# ChEBI_ID:
Not Available

# Chemical_Formula:
C41H67NO15

# Chemical_IUPAC_Name:
(3R,5R,6S,7S,8R,11R,12S,13R,14S,15S)-14-{[(2S,3R,4S,6R)-3-(acetyloxy)-4-(dimethylamino)-6-methyloxan-2-yl]oxy}-12-{[(2R,4S,5S,6S)-5-(acetyloxy)-4-methoxy-6-methyloxan-2-yl]oxy}-5,7,8,11,13,15-hexamethyl-4,10-dioxo-1,9-dioxaspiro[2.13]hexadecan-6-yl acetate

# Chemical_Structure:
Not Available

# Creation_Date:
2007-07-06 13:54:07 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A macrolide antibiotic that is similar to erythromycin.

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Anti-Bacterial Agents
Antibacterial Agents
Macrolides

# Drug_Interactions:
Aminophylline	The macrolide, troleandomycin, may increase the effect and toxicity of theophylline derivative, aminophylline.
Aprepitant	This CYP3A4 inhibitor increases the effect and toxicity of aprepitant
Astemizole	Increased risk of cardiotoxicity and arrhythmias
Carbamazepine	The macrolide, troleandomycin, may increase the effect of carbamazepine.
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Citalopram	Possible serotoninergic syndrome with this combination
Colchicine	Severe colchicine toxicity can occur
Cyclosporine	The macrolide, troleandomycin, may increase the effect of cyclosporine.
Dihydroergotamine	Possible ergotism and severe ischemia with this combination
Eletriptan	The macrolide, troleandomycin, may increase the effect and toxicity of eletriptan.
Eplerenone	The macrolide, troleandomycin, may increase the effect and toxicity of eplerenone.
Ergotamine	Possible ergotism and severe ischemia with this combination
Erlotinib	This CYP3A4 inhibitor increases levels/toxicity of erlotinib
Fluoxetine	Possible serotoninergic syndrome with this combination
Methysergide	Possible ergotism and severe ischemia with this combination
Oxtriphylline	The macrolide, troleandomycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
Pimozide	Increased risk of cardiotoxicity and arrhythmias
Tacrolimus	The macrolide antibiotic, Troleandomycin, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Troleandomycin therapy is initiated, discontinued or altered.
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Theophylline	The macrolide, troleandomycin, may increase the effect and toxicity of theophylline.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Troleandomycin

# HET_ID:
TAO

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41+/m0/s1

# InChI_Key:
InChIKey=LQCLVBQBTUVCEQ-QTFUVMRISA-N

# Indication:
For the treatment of Pneumococcal pneumonia due to susceptible strains and group A beta-hemolytic streptococcal infections of the upper respiratory tract.

# KEGG_Compound_ID:
C12753

# KEGG_Drug_ID:
D01322

# LIMS_Drug_ID:
1361

# Mechanism_Of_Action:
Troleandomycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the "P" or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the "A" or acceptor site to the "P" or donor site is prevented, and subsequent protein synthesis is inhibited.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
813.9684

# Molecular_Weight_Mono:
813.451070479

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA127840611

# Pharmacology:
Troleandomycin is a macrolide antibiotic that is similar to erythromycin. It is active in vitro against the following gram-positive organisms: <i>Streptococcus pyogenes</i> and <i>Diplococcus pneumoniae</i>.

# Predicted_LogP_Hydrophobicity:
3.76

# Predicted_LogS:
-4.6

# Predicted_Water_Solubility:
1.92e-02 g/l

# Primary_Accession_No:
DB01361

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
202225

# PubChem_Substance_ID:
46508062

# RxList_Link:
http://www.rxlist.com/cgi/generic/troleandomycin.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Oleandocetine
Oleandomycin triacetate
Oleandomycin triacetyl ester
Oleandomycin, triacetate (ester)
Triacetyloleandomycin

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include diarrhea, nausea, stomach cramps, and vomiting.

# Update_Date:
2013-02-08 16:20:06 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Troleandomycin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A5

# Phase_1_Metabolizing_Enzyme_1_ID:
4118

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A5

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P20815

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_2_ID:
4512

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_3_ID:
4757

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P11712

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP2C8

# Phase_1_Metabolizing_Enzyme_4_ID:
4924

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 2C8

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P10632

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
CYP2A6

# Phase_1_Metabolizing_Enzyme_5_ID:
5718

# Phase_1_Metabolizing_Enzyme_5_Name:
Cytochrome P450 2A6

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Cytochrome P450 2A6
MLASGMLLVALLVCLTVMVLMSVWQQRKSKGKLPPGPTPLPFIGNYLQLNTEQMYNSLMK
ISERYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVVFSN
GERAKQLRRFSIATLRDFGVGKRGIEERIQEEAGFLIDAHRGTGGANIDPTFFLSRTVSN
VISSIVFGDRFDYKDKEFLSLLRMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFQL
LQGLEDFIAKKVEHNQRTLDPNSPRDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFI
GGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQ
RFGDVIPMSLARRVKKDTKFRDFFLPKGTEVYPMLGSVLRDPSFFSNPQDFNPQHFLNEK
GQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVGF
ATIPRNYTMSFLPR

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P11509

# Phase_1_Metabolizing_Enzyme_6_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_6_ID:
6016

# Phase_1_Metabolizing_Enzyme_6_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_6_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_6_SwissProt_ID:
P33261

# Phase_1_Metabolizing_Enzyme_7_Gene_Name:
CYP3A43

# Phase_1_Metabolizing_Enzyme_7_ID:
6031

# Phase_1_Metabolizing_Enzyme_7_Name:
Cytochrome P450 3A43

# Phase_1_Metabolizing_Enzyme_7_Protein_Sequence:
>Cytochrome P450 3A43
MDLIPNFAMETWVLVATSLVLLYIYGTHSHKLFKKLGIPGPTPLPFLGTILFYLRGLWNF
DRECNEKYGEMWGLYEGQQPMLVIMDPDMIKTVLVKECYSVFTNQMPLGPMGFLKSALSF
AEDEEWKRIRTLLSPAFTSVKFKEMVPIISQCGDMLVRSLRQEAENSKSINLKDFFGAYT
MDVITGTLFGVNLDSLNNPQDPFLKNMKKLLKLDFLDPFLLLISLFPFLTPVFEALNIGL
FPKDVTHFLKNSIERMKESRLKDKQKHRVDFFQQMIDSQNSKETKSHKALSDLELVAQSI
IIIFAAYDTTSTTLPFIMYELATHPDVQQKLQEEIDAVLPNKAPVTYDALVQMEYLDMVV
NETLRLFPVVSRVTRVCKKDIEINGVFIPKGLAVMVPIYALHHDPKYWTEPEKFCPERFS
KKNKDSIDLYRYIPFGAGPRNCIGMRFALTNIKLAVIRALQNFSFKPCKETQIPLKLDNL
PILQPEKPIVLKVHLRDGITSGP

# Phase_1_Metabolizing_Enzyme_7_SwissProt_ID:
Q9HB55

# Phase_1_Metabolizing_Enzyme_8_Gene_Name:
CYP2C18

# Phase_1_Metabolizing_Enzyme_8_ID:
6106

# Phase_1_Metabolizing_Enzyme_8_Name:
Cytochrome P450 2C18

# Phase_1_Metabolizing_Enzyme_8_Protein_Sequence:
>Cytochrome P450 2C18
MDPAVALVLCLSCLFLLSLWRQSSGRGRLPSGPTPLPIIGNILQLDVKDMSKSLTNFSKV
YGPVFTVYFGLKPIVVLHGYEAVKEALIDHGEEFSGRGSFPVAEKVNKGLGILFSNGKRW
KEIRRFCLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTNASPCDPTFILGCAPCNVICS
VIFHDRFDYKDQRFLNLMEKFNENLRILSSPWIQVCNNFPALIDYLPGSHNKIAENFAYI
KSYVLERIKEHQESLDMNSARDFIDCFLIKMEQEKHNQQSEFTVESLIATVTDMFGAGTE
TTSTTLRYGLLLLLKYPEVTAKVQEEIECVVGRNRSPCMQDRSHMPYTDAVVHEIQRYID
LLPTNLPHAVTCDVKFKNYLIPKGTTIITSLTSVLHNDKEFPNPEMFDPGHFLDKSGNFK
KSDYFMPFSAGKRMCMGEGLARMELFLFLTTILQNFNLKSQVDPKDIDITPIANAFGRVP
PLYQLCFIPV

# Phase_1_Metabolizing_Enzyme_8_SwissProt_ID:
P33260

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
6972981	Scharre KA, Eckels DD, Gershwin ME: Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
D63900

# Drug_Target_1_GenBank_ID_Protein:
970089

# Drug_Target_1_GeneCard_ID:
rpmF

# Drug_Target_1_Gene_Name:
rpmF

# Drug_Target_1_Gene_Sequence:
>183 bp
ATGGCCAAACACCCCGTTCCCAAGAAGAAGACCAGCAAGAGCAAGCGCGACATGCGCCGC
AGCCACCACGCGCTGACCGCCCCCAACCTGACCGAGTGCCCCCAGTGCCACGGCAAGAAG
CTCTCGCACCACATCTGCCCCAACTGCGGCTATTACGATGGCCGTCAGGTGCTCGCGGTC
TAA

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
10567266	White O, Eisen JA, Heidelberg JF, Hickey EK, Peterson JD, Dodson RJ, Haft DH, Gwinn ML, Nelson WC, Richardson DL, Moffat KS, Qin H, Jiang L, Pamphile W, Crosby M, Shen M, Vamathevan JJ, Lam P, McDonald L, Utterback T, Zalewski C, Makarova KS, Aravind L, Daly MJ, Minton KW, Fleischmann RD, Ketchum KA, Nelson KE, Salzberg S, Smith HO, Venter JC, Fraser CM: Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1. Science. 1999 Nov 19;286(5444):1571-7.
11677599	Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F: Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
11733066	Harms J, Schluenzen F, Zarivach R, Bashan A, Gat S, Agmon I, Bartels H, Franceschi F, Yonath A: High resolution structure of the large ribosomal subunit from a mesophilic eubacterium. Cell. 2001 Nov 30;107(5):679-88.
12535524	Bashan A, Agmon I, Zarivach R, Schluenzen F, Harms J, Berisio R, Bartels H, Franceschi F, Auerbach T, Hansen HA, Kossoy E, Kessler M, Yonath A: Structural basis of the ribosomal machinery for peptide bond formation, translocation, and nascent chain progression. Mol Cell. 2003 Jan;11(1):91-102.
12623020	Schlunzen F, Harms JM, Franceschi F, Hansen HA, Bartels H, Zarivach R, Yonath A: Structural basis for the antibiotic activity of ketolides and azalides. Structure. 2003 Mar;11(3):329-38.
12665853	Berisio R, Schluenzen F, Harms J, Bashan A, Auerbach T, Baram D, Yonath A: Structural insight into the role of the ribosomal tunnel in cellular regulation. Nat Struct Biol. 2003 May;10(5):366-70.
15059283	Harms JM, Schlunzen F, Fucini P, Bartels H, Yonath A: Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol. 2004 Apr 1;2:4.
15554968	Schlunzen F, Pyetan E, Fucini P, Yonath A, Harms JM: Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6174

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
6791.9

# Drug_Target_1_Name:
50S ribosomal protein L32

# Drug_Target_1_Number_of_Residues:
60

# Drug_Target_1_PDB_ID:
1YL3

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01783	Ribosomal_L32p

# Drug_Target_1_Protein_Sequence:
>50S ribosomal protein L32
MAKHPVPKKKTSKSKRDMRRSHHALTAPNLTECPQCHGKKLSHHICPNCGYYDGRQVLAV

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Forms a cluster with L17 and L22, and with L22, a pair of "tweezers" that hold together all the domains of the 23S rRNA. Interacts with the antibiotic troleandomycin which blocks the peptide exit tunnel

# Drug_Target_1_SwissProt_ID:
P49228

# Drug_Target_1_SwissProt_Name:
RL32_DEIRA

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
10.48

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
6972981	Scharre KA, Eckels DD, Gershwin ME: Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5.

# Drug_Target_2_Essentiality:
Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X02613

# Drug_Target_2_GenBank_ID_Protein:
42826

# Drug_Target_2_GeneCard_ID:
rplD

# Drug_Target_2_Gene_Name:
rplD

# Drug_Target_2_Gene_Sequence:
>312 bp
ATGCAGAACCAAAGAATCCGTATCCGCCTGAAAGCGTTTGATCATCGTCTGATCGATCAA
GCAACCGCGGAAATCGTCGAGACTGCCAAGCGCACTGGTGCGCAGGTCCGTGGTCCGATC
CCGCTGCCGACACGCAAAGAGCGCTTCACTGTTCTGATCTCCCCGCACGTCAACAAAGAC
GCGCGCGATCAGTACGAAATCCGTACTCACTTGCGTCTGGTTGACATCGTTGAGCCAACC
GAGAAAACCGTTGATGCTCTGATGCGTCTGGATCTGGCTGCCGGTGTAGACGTGCAGATC
AGCCTGGGTTAA

# Drug_Target_2_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_2_General_References:
16738553	Hayashi K, Morooka N, Yamamoto Y, Fujita K, Isono K, Choi S, Ohtsubo E, Baba T, Wanner BL, Mori H, Horiuchi T: Highly accurate genome sequences of Escherichia coli K-12 strains MG1655 and W3110. Mol Syst Biol. 2006;2:2006.0007. Epub 2006 Feb 21.
2442760	Freedman LP, Zengel JM, Archer RH, Lindahl L: Autogenous control of the S10 ribosomal protein operon of Escherichia coli: genetic dissection of transcriptional and posttranscriptional regulation. Proc Natl Acad Sci U S A. 1987 Sep;84(18):6516-20.
3298242	Herold M, Nierhaus KH: Incorporation of six additional proteins to complete the assembly map of the 50 S subunit from Escherichia coli ribosomes. J Biol Chem. 1987 Jun 25;262(18):8826-33.
3892488	Zurawski G, Zurawski SM: Structure of the Escherichia coli S10 ribosomal protein operon. Nucleic Acids Res. 1985 Jun 25;13(12):4521-6.
4589347	Wittmann HG, Stoffler G, Apirion D, Rosen L, Tanaka K, Tamaki M, Takata R, Dekio S, Otaka E: Biochemical and genetic studies on two different types of erythromycin resistant mutants of Escherichia coli with altered ribosomal proteins. Mol Gen Genet. 1973 Dec 20;127(2):175-89.
6170935	Wower I, Wower J, Meinke M, Brimacombe R: The use of 2-iminothiolane as an RNA-protein cross-linking agent in Escherichia coli ribosomes, and the localisation on 23S RNA of sites cross-linked to proteins L4, L6, L21, L23, L27 and L29. Nucleic Acids Res. 1981 Sep 11;9(17):4285-302.
7556101	Urlaub H, Kruft V, Bischof O, Muller EC, Wittmann-Liebold B: Protein-rRNA binding features and their structural and functional implications in ribosomes as determined by cross-linking studies. EMBO J. 1995 Sep 15;14(18):4578-88.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-62.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6173

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
22086.4

# Drug_Target_2_Name:
50S ribosomal protein L4

# Drug_Target_2_Number_of_Residues:
201

# Drug_Target_2_PDB_ID:
1P86

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00573	Ribosomal_L4

# Drug_Target_2_Protein_Sequence:
>50S ribosomal protein L4
MELVLKDAQSALTVSETTFGRDFNEALVHQVVVAYAAGARQGTRAQKTRAEVTGSGKKPW
RQKGTGRARSGSIKSPIWRSGGVTFAARPQDHSQKVNKKMYRGALKSILSELVRQDRLIV
VEKFSVEAPKTKLLAQKLKDMALEDVLIITGELDENLFLAARNLHKVDVRDATGIDPVSL
IAFDKVVMTADAVKQVEEMLA

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Can regulate expression from Citrobacter freundii, Haemophilus influenzae, Morganella morganii, Salmonella typhimurium, Serratia marcescens, Vibrio cholerae and Yersinia enterocolitica (but not Pseudomonas aeruginosa) S10 leaders in vitro

# Drug_Target_2_SwissProt_ID:
P60723

# Drug_Target_2_SwissProt_Name:
RL4_ECOLI

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
10.45

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01361
